Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00341705 · ClinicalTrials.gov registry record
The Second Multicenter Hemophilia Cohort Study
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 2,565
- Enrollment target
NCT00341705: Completed study, sponsored by National Cancer Institute (NCI).
NCT00341705 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 2,565 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00341705 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 2,565 participants
- Enrollment target
Study Summary
The Second Multicenter Hemophilia Cohort Study (MHCS-II) will evaluate and prospectively follow approximately 4500 persons with hemophilia who were exposed to hepatitis C virus (HCV). The vast majority will have been infected with HCV, and approximately 1/3 will have been infected with human immunodeficiency virus (HIV). Primary objectives are to quantify the rates of liver decompensation, hepatocellular carcinoma, and non-Hodgkin lymphoma and to evaluate candidate clinical, genetic, virologic, serologic and immunologic markers that are likely to be on the causal pathway for these conditions. Candidate clinical and laboratory markers will be examined longitudinally to define changes over time and their relationships to one another. Collaborative studies will focus on genome scanning and evaluation of candidate genetic loci for susceptibility or resistance to HCV and HIV infections or to the diseases that result from these infections. Additional studies will identify response and complication rates of various anti-HCV and anti-HIV regimens in the setting of comprehensive clinical care of persons with hemophilia.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,565 participants |
| Start Date | 2001-04-27 |
| Est. Completion | 2013-04-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00341705
The ClinicalTrials.gov registry entry for NCT00341705 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,565 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00341705 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00341705 about?
NCT00341705 is a clinical study titled "The Second Multicenter Hemophilia Cohort Study". The Second Multicenter Hemophilia Cohort Study (MHCS-II) will evaluate and prospectively follow approximately 4500 persons with hemophilia who were exposed to hepatitis C virus (HCV). The vast majority will have been infected with HCV, and approximately 1/3 will have been infected with human immunod...
What is the current status of trial NCT00341705?
This trial is currently completed. The enrollment target is 2,565 participants. The study started on 2001-04-27. Estimated completion is 2013-04-02.
Who is sponsoring clinical trial NCT00341705?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.